QuidelOrtho Files 8-K on Feb 16, 2024

TL;DR

**QuidelOrtho just filed an 8-K for Regulation FD Disclosure on Feb 16, 2024, keeping the market informed.**

AI Summary

QuidelOrtho Corporation filed an 8-K on February 16, 2024, under Regulation FD Disclosure. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 16, 2024. The company, based in San Diego, California, with IRS Employer Identification No. 87-4496285, is a Delaware corporation.

Why It Matters

This 8-K filing ensures public disclosure of material non-public information, maintaining transparency and compliance with SEC regulations for QuidelOrtho Corporation.

Risk Assessment

Risk Level: low — This is a routine disclosure filing, not indicating any specific financial or operational risks.

Key Numbers

• 20240216 — Filing Date (Date the 8-K was filed and earliest event reported)
• 001-41409 — Commission File Number (SEC identification for QuidelOrtho)
• 87-4496285 — IRS Employer Identification No. (Tax identification for QuidelOrtho)

Key Players & Entities

• QuidelOrtho Corporation (company) — Registrant
• February 16, 2024 (date) — Date of Report and earliest event reported
• Delaware (company) — State of incorporation
• 87-4496285 (dollar_amount) — IRS Employer Identification No.
• San Diego, California (company) — Principal executive offices location

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value QDEL The Nasdaq Stock Market
• $2.76 — s follows: Total revenues (reported) $2.76 - $3.07 billion Non-respiratory reven
• $3.07 billion — s: Total revenues (reported) $2.76 - $3.07 billion Non-respiratory revenue $2.30 - $2.3
• $2.30 — 3.07 billion Non-respiratory revenue $2.30 - $2.34 billion Respiratory revenue
• $2.34 billion — lion Non-respiratory revenue $2.30 - $2.34 billion Respiratory revenue $460 - $730 mill
• $460 — - $2.34 billion Respiratory revenue $460 - $730 million Adjusted EBITDA $565
• $730 million — 4 billion Respiratory revenue $460 - $730 million Adjusted EBITDA $565 - $720 million
• $565 — $460 - $730 million Adjusted EBITDA $565 - $720 million Adjusted EBITDA % 21%
• $720 million — $730 million Adjusted EBITDA $565 - $720 million Adjusted EBITDA % 21% - 24% Adjust
• $1.88 — DA % 21% - 24% Adjusted diluted EPS $1.88 - $3.60 The information in this Form
• $3.60 — % - 24% Adjusted diluted EPS $1.88 - $3.60 The information in this Form 8-K is b

Filing Documents

• qdel-20240216.htm (8-K) — 30KB
• 0001906324-24-000006.txt ( ) — 181KB
• qdel-20240216.xsd (EX-101.SCH) — 2KB
• qdel-20240216_def.xml (EX-101.DEF) — 14KB
• qdel-20240216_lab.xml (EX-101.LAB) — 27KB
• qdel-20240216_pre.xml (EX-101.PRE) — 15KB
• qdel-20240216_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 13, 2024, QuidelOrtho Corporation ("QuidelOrtho" or the "Company") issued a press release announcing the financial results for its fourth quarter and full year ended December 31, 2023, which included QuidelOrtho's fiscal year 2024 financial guidance (the "2024 Guidance"). On February 13, 2024, QuidelOrtho also posted supplemental investor materials on its ir.quidelortho.com website, which also included the 2024 Guidance. QuidelOrtho is furnishing this Current Report on Form 8-K ("Form 8-K") to make a correction to its 2024 Guidance to widen the range for adjusted diluted EPS to align with 2024 Guidance for adjusted EBITDA, for which the mid-point of the adjusted diluted EPS range remains unchanged. The following is QuidelOrtho's corrected 2024 Guidance: Fiscal Year 2024 Financial Guidance Based on its current business outlook, the Company is providing fiscal year 2024 financial guidance, as follows: Total revenues (reported) $2.76 - $3.07 billion Non-respiratory revenue $2.30 - $2.34 billion Respiratory revenue $460 - $730 million Adjusted EBITDA $565 - $720 million Adjusted EBITDA % 21% - 24% Adjusted diluted EPS $1.88 - $3.60 The information in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 16, 2024 QUIDELORTHO CORPORATION By: /s/ Joseph M. Busky Name: Joseph M. Busky Its: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR